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Abstract The reproductive-cell cycle theory of aging
posits that reproductive hormone changes associated
with menopause and andropause drive senescence via
altered cell cycle signaling. Using data from the
Wisconsin Longitudinal Study (n=5,034), we ana-
lyzed the relationship between longevity and meno-
pause, including other factors that impact “ovarian
lifespan” such as births, oophorectomy, and hormone
replacement therapy. We found that later onset of
menopause was associated with lower mortality, with
and without adjusting for additional factors (years of
education, smoking status, body mass index, and
marital status). Each year of delayed menopause
resulted in a 2.9% reduction in mortality; after
including a number of additional controls, the effect
was attenuated modestly but remained statistically
significant (2.6% reduction in mortality). We also
found that no other reproductive parameters assessed
added to the prediction of longevity, suggesting that
reproductive factors shown to affect longevity else-
where may be mediated by age of menopause. Thus,
surgical and natural menopause at age 40, for
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example, resulted in identical survival probabilities.
These results support the maintenance of the hypo-
thalamic–pituitary–gonadal axis in homeostasis in
prolonging human longevity, which provides a coher-
ent framework for understanding the relationship
between reproduction and longevity.
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Introduction
The reproductive-cell cycle theory of aging postu-
lates that the hormones that regulate reproduction
act in an antagonistic pleiotropic manner to control
aging via cell cycle signaling; they promote
growth and development early in life to achieve
reproduction but later in life, in a futile attempt to
maintain reproduction, become dysregulated and
drive senescence (Bowen and Atwood 2004). Thus,
the dysregulation of the hypothalamic–pituitary–go-
nadal (HPG) axis (endocrine dyscrasia) leads to
altered (dyotic) signaling to somatic and reproductive
tissues, driving re-entry of cells into the cell cycle. In
post-mitotic, terminally differentiated cell types, such
signaling leads to attempted, albeit incomplete, cell
division resulting in cellular dysfunction and/or death.
In tissues containing totipotent stem cells, cellular
division is completed at an enhanced rate.
The theory predicts that the longer the HPG axis is
maintained in equilibrium, the longer an organism
will live. Support for the dysregulation of the HPG
axis in regulating lifespan comes from both animal
and human studies (Helle et al. 2005; Horiuchi 1997).
The most frequently reported relationship between
reproduction and post-reproductive survival in
humans is between late reproduction and longevity,
with advanced age at last reproduction associated
with improved longevity (Helle et al. 2005, Appendix
A). In this study, we examined a number of
reproductive life traits to determine whether mainte-
nance of the HPG axis predicts increased longevity.
We find that later age of menopause is consistently
associated with reduced mortality among women in
the Wisconsin Longitudinal Study (WLS) and that no
other reproductive parameter assessed significantly
predicted mortality. These results suggest that repro-
ductive and somatic senescence are tightly coupled in
humans and that selection to reproduce later (or
longer) would favor enhanced longevity. Our findings
suggest that strategies designed to maintain the HPG
axis in equilibrium will increase longevity.
Methods
Data
The WLS design and history have been discussed in
detail elsewhere (Hauser 2005; Hauser and Willis
2005; Sewell et al. 2004). Briefly, the WLS sample
was originally comprised of 10,317 men and women
who graduated from Wisconsin high schools in 1957
(one third of all who graduated, the modal year of birth
was 1939). These individuals were surveyed in 1964,
1975, 1992, 2004, and 2010 (current round).1 In
addition to the focal respondents, the WLS began
interviewing one randomly selected sibling of each
graduate (when possible) starting in 1977 (were
mainly born between 1929 and 1949). Since then
the survey content has been broadly parallel for
graduate and sibling participants.
The WLS provides a comprehensive record of social
background, adolescent ability and aspirations, school-
ing, military service, family formation, labor market
experiences, health, personality, and social and civic
participation of the original respondents. Data for the
current study come primarily from the 1993 and 2004
waves of the WLS when female reproductive health and
menopause questions were added to the supplemental
mail surveys. These data were augmented with National
Death Index (NDI) and Social Security Death Master
File (SSA) death records.
Sample and response rates
The WLS has and continues to enjoy exceptional
response rates. The WLS sample includes 5,326
female graduates (original sample) and 4,341 ran-
1 Other than a nominal $10 payment included in the 2004 mail
survey, WLS respondents have never been reimbursed for
participation.
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domly selected female siblings (supplemental sample,
from graduates of either gender).2 Of these, 7,344
were able to be located, alive, and sent a mail survey
in the 1993 interview round. We take this as the base
sample for computing response rates. A total of 5,827
(72%) sample members completed the mail survey.
Notably, 276 of these cases (5%) were still menstru-
ating at last contact and excluded from analysis. Data




Death was the primary outcome measure for this
study. Death records were collected from two sources:
(1) the NDI, a national registry of deaths from local
and state reporting agencies with near complete
coverage of domestic deaths, and/or (2) SSA, a death
registry compiled by the Social Security Administra-
tion of Social Security beneficiaries. Records were
first matched with the NDI. If a match was found
using NDI confirming a death, the date of death was
recorded. At the time of this study, NDI death
information was available up through December
2008. To ascertain deaths after December 2008 or
for records not in the NDI, we matched records with
the SSA. Though SSA records may have somewhat
lower coverage than NDI records, they were both
more current (available through June 2010) and less
likely to contain reporting errors for crucial matching
information (e.g., social security number, date of
birth). If a death match was found in the SSA, the
date of death was recorded. Records not matching
NDI, SSA, or WLS internal mortality records were
presumed alive as of June 2010.
Reproductive traits
Data on menopause, number of live births, unilateral
and bilateral oophorectomy, hysterectomy, and hor-
mone replacement therapy (HRT) were collected. Age
of menopause—approximated by age of last menstru-
al period—was constructed from a combination of
several items, including age of last menstrual cycle,
menstruation within the last 12 months, and age at
time of survey. Menopause and reproductive health
data (surgery, HRT, etc.) were primarily extracted
from the 1993 survey and updated, if necessary, from
information collected at follow-up in 2004. Number
of live births was collected from rosters of children
that were updated at each survey wave.
Other factors
Other covariates investigated were year of birth,
adolescent IQ, years of education, marital status,
family income, smoking status, and body mass index
(BMI).4 These were collected at baseline (1993) or
from administrative records. See Table 1 for sample
descriptive statistics.
Analyses
We used a prospective analytic design. We estimated
two sets of proportional hazards regressions predict-
ing mortality risk, with and without covariates (Cox
1972; SAS Institute 2011).5 These types of models
relate time-to-event data to a set of covariates and an
underlying hazard function. These models included
both right and left censoring; right censoring was used
for post-survey survival, while left censoring was
used to account for survival from age of last period to
age at survey. We also used a robust standard error
correction for sibling pairs.
Preliminary models included all the controls listed
in other factors above. Non-significant controls were
dropped from the final “adjusted” regressions pre-
sented below. The significant controls that were
retained were (a) years of education, (b) smoking
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2 Siblings were randomly selected from rosters of siblings
ascertained during the 1975 graduate telephone interviews.
However, some graduates declined to provide contact informa-
tion for selected siblings. This number represents the number of
female selected siblings regardless of whether contact informa-
tion was obtained and should be interpreted as the maximum
possible female sibling sample.
3 The primary reasons for incomplete data were individual item
refusal and/or unclassifiable responses.
4 Global self-reported health was excluded as a predictor as
menopause induces changes in global health.
5 We explored other analytic approaches, including predicting
5-year survival using logistic regression, with similar results.
status, (c) BMI, and (d) marital status. Preliminary
models also explored alternative specifications of age
at last period (i.e., age groups) with similar findings.
Results
The proportional hazards regression models indicated
that menopause significantly predicts mortality (see
Table 2). Unadjusted data indicated a 2.9% reduction
in mortality for every year of later menopause.
Adjusting for years of education, smoking status,
BMI, and marital status modestly attenuated the
reduction in mortality to 2.6%.
Estimated survival probabilities from these regres-
sions are shown in Table 3 and plotted in Figs. 1 and
2 between the ages of 50 and 90. The data weremodeled
to represent the majority of menopause ages in our
sample (40–55 years), with other controls evaluated at
their mean. These illustrate how increasing age at
menopause is associated with increased probability of
survival for both unadjusted and adjusted regression
models. Women in our sample who reached menopause
at 40 years of age had a 39% chance of surviving to age
90, while womenwho reachedmenopause at 55 years of
age had a 53% chance of surviving to age 90 (based on
adjusted regressions). For example, this reduction in
mortality (between menopause at age 55 vs 40)
translated into a life expectancy advantage over the 50-
90 age range of 1.58 years (4.6%).
Table 2 Proportional hazards regression results
Hazard ratio p 95% CI
Age of menopause (years)
Unadjusted 0.971 <0.001 0.959–0.983
Adjusteda 0.974 <0.001 0.962–0.986
a Adjusted for baseline education, smoking, BMI, and marital
status
Table 3 Estimated survival probabilities from age 50–90 by
age of last period
Age last period Estimated survival to agea
60 (%) 70 (%) 80 (%) 90 (%)
40 years 97 90 79 39
45 years 97 92 81 44
50 years 98 93 83 49
55 years 98 93 85 53
a Adjusted for baseline years of education, smoking status,
BMI, and marital status




Age at 1993 interview (SD) 54.1 (4.14) 35.7–77.8
Deaths
N (%) 439 (8.7%)
Age at death (SD) 65.9 (6.89) 51–91
Reproductive parameters
Age of last period (SD) 47.7 (7.08) 21–65
Biological children (SD) 2.8 (1.70) 0–18
Any HRT (%) 61.6%
Oophorectomy, one or both (%) 28.2%
Baseline and additional controls
Adolescent IQ (SD) 102.7 (14.6) 61–145
Years of education (SD) 13.4 (2.12) 2–21
Current smoker 17.5%
Body mass index (SD) 26.1 (5.16) 10–83
Currently married 80.0%
Median family income $47,600 −$12,000–$1,000,000
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However, other reproductive traits that we ex-
plored in preliminary work (unilateral or bilateral
oophorectomy, number of biological children, and
HRT) did not significantly contribute to predicting
mortality and were not included in our final regres-
sions. In other words, no other reproductive parame-
ters assessed added to the prediction of longevity,
with or without considering age of menopause. Thus,
surgical and natural menopause at age 40, for
example, resulted in identical survival probabilities.
It is important to note, however, that number of
biological children and HRT were significantly
associated with age of menopause. That is, number
of biological children was positively associated with
Fig. 1 Unadjusted survival
probability curves for wom-
en aged between 50 and 90
whose last menstrual period
occurred at 40, 45, 50, or
55 years of age
Fig. 2 Adjusted survival
probability curves for wom-
en aged between 50 and 90
whose last menstrual period
occurred at 40, 45, 50, or
55 years of age
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age of menopause, while use of HRT was negatively
associated with age of menopause. It is also important
to note that preliminary simulations did not suggest
that loss to follow-up or missing data would signif-
icantly alter our main findings.
Discussion
Our findings suggest that maintenance of HPG axis
homeostasis is a predictor of mortality. Later age of
last period consistently predicted reduced mortality
(Figs. 1 and 2; Table 2); even when adjusted for a
number of additional covariates, the effect remained
largely unchanged. We also found in our preliminary
regressions that surgical and natural menopause
resulted in identical survival probabilities, as might
be expected given that both result in the dysregulation
of the HPG axis.
These data fit within the biological and evolution-
ary framework of the reproductive-cell cycle theory of
aging that posits the endocrine dyscrasia resulting
from the loss of negative feedback by sex steroids and
inhibins on hypothalamic and pituitary hormonal
production is driving our senescent phenotype and
ultimately mortality. Thus, factors that regulate the
commencement (puberty), end (menopause, andro-
pause, oophorectomy), or modulation of HPG axis
homeostasis (pregnancy, lactation, amenorrhea, and
HRT) might be predicted to regulate senescence (age-
related diseases) and mortality. Below we discuss the
evidence for each of these factors with respect to age-
related disease incidence and longevity.
Age at menopause
Previous studies, together with our current study,
indicate that higher age at menopause is associated
with prolonged female post-reproductive lifespan
(Helle et al. 2005; Cooper et al. 1998; Jacobsen et
al. 1997, 2003; Johnston 2001, 2003; Ossewaarde et
al. 2005; Snowdon et al. 1989; van der Schouw et al.
1996). The most frequently reported relationship
between reproduction and post-reproductive survival
in humans is between late reproduction and longevity,
with advanced age at last reproduction being associ-
ated with improved longevity (Helle et al. 2005,
Appendix A). In addition, delaying of an entire
reproductive effort to later age covaries with the
enhanced post-reproductive survival of mothers
(Helle et al. 2002). Conversely, early menopause
induced by bilateral oophorectomy at the time of
hysterectomy for benign disease is associated with an
increased risk of morbidity and mortality (Parker and
Manson 2009; Parker et al. 2009; Rivera et al. 2009a,
b; Rocca et al. 2006). Oophorectomy is not associated
with increased survival at any age (Parker et al. 2009).
In this connection, it has been shown that experimental
manipulation of germ cell number affects longevity.
Transplantation of reproductively viable ovaries from
young mice into senescent mice significantly extended
lifespan (Cargill et al. 2003).
Further evidence that reproductive endocrine dys-
crasia lies at the heart of mortality is indicated by the
relationship between the age at menopause and age-
related diseases. In women with later menopause,
there is a reduced risk for developing cardiovascular
disease (de Kleijn et al. 2002; van der Schouw et al.
1996; Jacobsen et al. 1997; Hu et al. 1999;
Ossewaarde et al. 2005), calcifications in the aorta
(Witteman et al. 1989), atherosclerosis (Joakimsen et
al. 2000), cognitive decline (McLay et al. 2003), and
bone fractures (van Der Voort et al. 2003). The risk of
colorectal cancer also is decreased (van Wayenburg et
al. 2000), and despite an increase in death from
uterine and ovarian cancer with increasing age at
menopause, the net effect of later menopause is an
increased lifespan (Ossewaarde et al. 2005).
As might be expected, early reproductive endo-
crine dyscrasia, occurring naturally or induced by
unilateral or bilateral oophorectomy in premenopausal
women, is associated with increased risk of develop-
ing dementia, cognitive decline, stroke, fatal and non-
fatal coronary heart disease, Parkinsonism, osteopo-
rosis, hip fracture, lung cancer, depression, and
anxiety (Parker and Manson 2009; Parker et al.
2009; Rivera et al. 2009a, b; Rocca et al. 2006;
Nappi et al. 1999; Rocca et al. 2007; Shuster et al.
2010; Gleason et al. 2005; Rocca et al. 2008a, b, c,
2009; Lisabeth et al. 2009; Baba et al. 2010; Koushik
et al. 2009). Indeed, the increased prevalence of
cognitive disease in women correlates with the abrupt
earlier loss of gonadal function (Jorm et al. 1987;
McGonigal et al. 1993; Brookmeyer et al. 1998; Gao
et al. 1998; Andersen et al. 1999; Hy and Keller
2000). Prospective cohort studies indicate that E2
replacement therapy reduces the incidence (Henderson
et al. 1994) and delays the onset of cognitive decline
134 AGE (2013) 35:129–138
in women and men (Tang et al. 1996; Kawas et al.
1997; Paganini-Hill and Henderson 1996; Baldereschi
et al. 1998). It should be noted that similar protection is
not always afforded by the use of non-physiological
estrogens such as conjugated equine estrogens (CEE)
and non-physiological progestagens such as medrox-
yprogesterone (MPA; Shumaker et al, 2003). This
might explain the null finding in our study for HRT and
longevity, since most subjects taking HRT in the US
were prescribed either Premarin (CEE) or Prempro
(CEE + MPA). Similarly, suppression of circulating
gonadotropins (and sex steroids) with GnRH agonist
therapy halves the risk of death from AD (Bowen et al.
2004; D’Amico et al. 2010), suggesting elevations in
gonadotropins drive cognitive decline (Bryan et al.
2010; Casadesus et al. 2006, 2007). Indeed, it has
been demonstrated that down-regulation of serum
gonadotropins is as effective as estrogen replacement
at improving menopause-associated cognitive deficits
in mice (Bryan et al. 2010).
Breast and ovarian cancer are the only age-related
diseases where risk decreases with early reproductive
endocrine dyscrasia, i.e., following oophorectomy
(Parker et al. 2009). Conversely, early menarche,
higher numbers of ovulatory cycles, nulliparity, and
late menopause are associated with increased risk for
female reproductive cancers (Gladwell 2000; Parsa
and Parsa 2009).
Age at menarche
Just as earlier endocrine dyscrasia results in increased
mortality, so too early age at menarche (before age
12 years), is correlated with increased risk of
cardiovascular morbidity and mortality and overall
mortality in women (Lakshman et al. 2009). Con-
versely, two recent studies have found a 4.5% and
2.4% reduced risk of overall mortality for each year
later menarche occurs (Jacobsen et al. 2007, 2009).
However, it is not clear if later age at menarche
decreases risk of cardiovascular morbidity and mor-
tality, per se, or if later age of menarche operates
through later age of menopause as suggested by our
results. Since earlier menarche might be associated
with earlier menopause, with later menarche associ-
ating with later menopause, these data indicate that
maintaining the HPG axis in equilibrium longer, for
example, will decrease the risk of morbidity and
mortality.
Partial re-establishment of the HPG axis with HRT
The most compelling evidence in humans for
reproductive endocrine dyscrasia regulating lon-
gevity comes from epidemiological studies of
estrogen replacement therapy use after menopause.
Partial balancing of the HPG axis with estrogen
therapy (decreasing gonadotropin/GnRH produc-
tion) extends longevity. Over 15 studies have
demonstrated a reduction in the risk of mortality
in those taking estrogen replacement therapies
(reviewed in Paganini-Hill et al. 2006). These
studies consistently show a 20% to 50% decrease in
mortality among users of estrogens. Recently,
Paganini-Hill et al. (2006) reported increased longev-
ity even in older users of post-menopausal estrogen
therapy. There is considerable evidence that physio-
logical hormone replacement therapies also delay the
onset, halt the progression of, and even reverse the
course of age-related diseases including heart disease,
cerebrovascular disease (stroke), Alzheimer’s disease,
cancer, and osteoporosis (Atwood and Bowen 2011).
Thus, partial rebalancing of the HPG axis following
menopause and during andropause via exposure to
sex steroids increases longevity. Although there is
mounting evidence that the elevations in gonadotro-
pins promotes age-related diseases (Bowen et al.
2004; Wilson et al. 2008; Bryan et al. 2010; Atwood
and Bowen 2011; Sun et al. 2006), gonadotropins are
of course downregulated by sex steroids (and GnRH
agonists/antagonists). Thus, either the maintenance of
sex steroid concentrations or the suppression of
gonadotropin concentrations using sex steroids and/
or GnRH agonists/antagonists would be expected to
delay age-related diseases and extend longevity.
In animals, re-establishment of the negative feed-
back loops in the HPG axis of post-reproductive
mice (22 months of age) following transplantation
of reproductively viable ovaries from young mice
(3 months of age) has been demonstrated to
extend lifespan by up to 40% (Cargill et al.
2003; Mason et al. 2009). Gonad manipulation in
model organisms provides strong evidence for a direct
link between reproduction and longevity (Arantes-
Oliveira et al. 2002; Muller et al. 2001). In the
hermaphroditic worm Caenorhabditis elegans, neo-
natal ablation of the gonadal germ line cells while
leaving the somatic gonad intact results in increased
life span, but removal of the entire gonad yielded no
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change in life span (Hsin and Kenyon 1999).
Ablation of the germ line must be prior to germ line
stem cell proliferation for lifespan extension to occur
(Arantes-Oliveira et al. 2002). However, no extension
of lifespan was found following ablation of the
germ line in Drosophila melanogaster (Barnes
et al. 2006). Characterization and quantitation of
the endocrine signals in these animal models might
help explain the discrepant results regarding longev-
ity. In this respect, our own data indicate that
suppression of GnRHR signaling in C. elegans
significantly decreases reproduction 46% and
prolongs lifespan 15% (23% at lower temperature)
compared with wild-type worms (Vadakkadath
Meethal et al. 2006; Vadakkadath Meethal, and
Atwood, unpublished data).
Limitations
Our study is limited in a few ways. First, WLS
participants are almost exclusively non-Hispanic
white and grew up and have lived largely in
Wisconsin. Second, while our preliminary work
indicated that no other reproductive parameters were
significantly associated with mortality, we cannot
definitely rule out some other possible explanations
for our findings, like pre-existing health problems.
Third, our analyses relied exclusively on self-reported
data for all predictors. Fourth, because of relatively
low mortality in our sample and certain data limi-
tations, we were not able to disaggregate our analyses
by cause of death.
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